Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I DDI Study of Suraxavir Marboxil in Healthy Volunteers
NCT05789342Phase 1Completed
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of suraxavir marboxil in influenza (4 arms), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoints: Peak plasma concentration of Rosuvastatin, Area under the plasma concentration versus time curve of Rosuvastatin and 6 more. Started Feb 2023; status: completed.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05789342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789342.